Amit Etkin, Alto Neuroscience CEO

Al­to Neu­ro­science con­tin­ues march to­ward the clin­ic with Se­ries B, hop­ing to un­veil da­ta next year

A year ago, Al­to Neu­ro­science came in­to the game with a $32 mil­lion Se­ries A and plans to launch three Phase IIa tri­als for sev­er­al psy­chi­atric dis­or­ders, in­clud­ing treat­ment-re­sis­tant de­pres­sion and PTSD. The com­pa­ny, found­ed by Stan­ford neu­rol­o­gist Amit Etkin, was built around pre­dic­tive tech­nol­o­gy that his team said could pre­dict PTSD pa­tients’ re­sponse to ther­a­py by just look­ing at brain­waves.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.